## **AMENDMENTS TO THE CLAIMS**

1. (Currently amended). The use of pyrazolidinedione derivatives of the general formula A method for preventing or treating a disease or a condition associated with platelet aggregation, said method comprising administering to a mammal in need thereof at least one compound selected from the group consisting of:

## a pyrazolidinedione derivative of formula (I),

$$R_1$$
 $R_2$ 
 $R_1$ 
 $R_2$ 
 $R_1$ 

## wherein

R<sub>1</sub> is hydrogen, optionally substituted alkyl, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl or alkanoyl; and

R<sub>2</sub> is aryl or heteroaryl[[;]],

tautomers thereof[[; and]],

geometric isomers thereof [[and]] <u>or</u> tautomers of these geometric isomers[[,]]; <u>and</u>

<u>a mixture thereof;</u> including mixtures of individual compounds of formula (I), or tautomers thereof, and their geometric isomers, or tautomers thereof; <u>or</u>

<u>a</u> pharmaceutically acceptable acid addition salts of compounds which are basic <u>salt of said compound</u> which is basic; or

<u>a</u> pharmaceutically acceptable salts of compounds containing acidic groups with bases salt of said compound containing an acidic group with a base; or

<u>a</u> pharmaceutically acceptable <u>esters of compounds</u> <u>ester of said compound</u> containing <u>a</u> hydroxy or carboxy <u>groups</u> <u>group</u>; <u>or</u>

prodrugs of compounds a prodrug of said compound in which a prodrug forming group is present; as well as hydrates or solvates or a hydrate or solvate thereof;

as platelet adenosine diphosphate receptor antagonists for the prevention and/or treatment of peripheral vascular, of visceral-, hepatic- and renal-vascular, of cardiovascular and of cerebrovascular diseases or conditions associated with platelet aggregation and, respectively, for the manufacture of corresponding medicaments.

- 2. (Currently amended) The [[use]]  $\underline{\text{method}}$  according to claim 1, wherein  $R_1$  is other than alkanoyl.
- 3. (Currently amended) The [[use]] <u>method</u> according to claim 1, [[or 2]] wherein the disease or condition is thrombosis.
- 4. (Currently amended) The [[use]] method according to claim 1, [[or 3]] wherein R<sub>1</sub> is hydrogen, alkyl, aryl, heteroaryl or alkanoyl.
- 5. (Currently amended) The [[use]] method according to claim 4, wherein R<sub>1</sub> is hydrogen, alkyl, phenyl, bromophenyl, chlorophenyl, fluorophenyl, methylphenyl, methoxyphenyl, cyanophenyl, alkoxycarbonylphenyl, pyridinyl or alkanoyl.
- 6. (Currently amended) The [[use]] method according to claim 5, wherein R<sub>1</sub> is hydrogen, methyl, phenyl, 2-pyridinyl, 4-pyridinyl, 2-methylphenyl, 4-methylphenyl, 4-methoxyphenyl, 2-chlorophenyl, 4-fluorophenyl, 4-bromophenyl, 4-cyanophenyl, 4-ethoxycarbonylphenyl or acetyl.

4

7. (Currently amended) The [[use]]  $\underline{\text{method}}$  according to  $\underline{\text{any one of claims 1}}$  to 6  $\underline{\text{claim 1}}$ , wherein  $R_2$  is naphthalenyl, thienyl or pyridyl.

- 8. (Currently amended) The [[use]] method according to claim 7, wherein R<sub>2</sub> is naphthalen-2-yl, pyridin-3-yl or thiophen-3-yl.
- 9. (Currently amended) The [[use]] method according to any one of claims 1 to 3 of compounds of the general claim 1, wherein said compound is at least one selected from the group consisting of:

a pyrazolidinedione derivative of formula (III),

$$R_3$$
 $R_4$ 
 $R_5$ 
 $R_5$ 
 $R_5$ 

including their geometric isomers thereof, [[and]] tautomers thereof and mixtures thereof; as well as their salts, esters and prodrugs mentioned in claim 1 or a salt, ester or prodrug of said compound,

wherein

R<sub>1</sub> is as defined in any one of claims 1, 2 and 4 to 6;

R<sub>3</sub> is hydrogen, alkyl, alkenyl, alkynyl, alkoxy, hydroxyalkoxy, alkoxyalkoxy, alkenyloxy, cycloalkyzy, cycloalkyzylalkoxy or alkylsulfonyloxy;

R<sub>4</sub> is hydrogen, halogen, hydroxy, alkyl or alkoxy; and

R<sub>5</sub> is hydrogen, halogen, hydroxy, alkyl, alkoxy, alkoxyalkoxy, hydroxyalkoxy, dihydroxyalkoxy, alkanoyloxyalkoxy, carboxyalkoxy,

carboxy-hydroxyalkoxy, carboxy-dihydroxyalkoxy, alkoxycarbonylalkoxy, alkoxycarbonyl-hydroxyalkoxy, alkoxycarbonyl-dihydroxyalkoxy, carbamoylalkoxy, *N*-alkylcarbamoylalkoxy, *N*,*N*-dialkyaminolalkoxy, morpholin-4-ylalkoxy, piperidin-1-ylalkoxy, morpholin-4-ylcarbonylalkoxy, 2,2-dialkyl[1,3]dioxolan-4-ylalkoxy or 2,2-dialkyl-4-carboxy[1,3]dioxolan-5-ylalkoxy; or

R<sub>4</sub> [[und]] <u>and</u> R<sub>5</sub>, together with the phenyl ring to which they are attached, form a fused, optionally substituted carbocyclic or heterocyclic ring system.

10. (Currently amended) The [[use]] method according to claim 9, wherein

R<sub>1</sub> is other than alkanoyl;

R<sub>3</sub> is hydrogen, alkyl, alkenyl, alkynyl, alkoxy, hydroxyalkoxy, alkoxyalkoxy, alkenyloxy, cycloalkoxy or cycloalkylalkoxy; and

R<sub>4</sub> and R<sub>5</sub>, each independently of the other, are hydrogen, halogen, hydroxy, alkyl or alkoxy; or

 $R_4$  [[und]] <u>and</u>  $R_5$ , together with the phenyl ring to which they are attached, form a fused, optionally substituted carbocyclic or heterocyclic ring system.

11. (Currently amended) The [[use]] method according to claim 9, [[or 10]] wherein

R<sub>3</sub> is alkyl, alkenyl, alkynyl, alkoxy, cycloalkoxy, cycloalkylalkoxy, hydroxyalkoxy or alkoxyalkoxy; and

 $R_4$  and  $R_5$  both are hydrogen, or  $R_4$  is halogen, alkyl or alkoxy and  $R_5$  is hydrogen, or  $R_4$  and  $R_5$  each independently are alkyl or alkoxy.

(Currently amended) The [[use]] method according to claim 11
 wherein

R<sub>3</sub> is methyl, ethyl, propyl, *iso*-propyl, butyl, *iso*-butyl, *tert*-butyl, pentyl, hexyl, but-1-enyl, pent-1-enyl, but-1-ynyl, pent-1-ynyl, methoxy, ethoxy, propoxy, butoxy, *iso*-butoxy, 3-methyl-butoxy, pentyloxy, cyclopentyloxy, hexyloxy, cyclopropylmethoxy, cyclobutylmethoxy, 2-hydroxy-ethoxy, or 2-methoxy-ethoxy, and

 $R_4$  and  $R_5$  both are hydrogen or  $R_4$  is chloro, bromo, methyl or methoxy and  $R_5$  is hydrogen, or  $R_4$  and  $R_5$  each independently are methyl or methoxy.

13. (Currently amended) The [[use]] method according to claim 9, [[or 10]] wherein

R<sub>3</sub> is hydrogen or alkoxy; and

R<sub>4</sub> and R<sub>5</sub> together with the phenyl ring to which they are attached, form an optionally substituted naphthalene, tetrahydronaphthalene, indane, 1*H*-indene, isoquinoline, dihydro-benzo[1,4]dioxine or benzo[1,3]dioxole moiety.

14. (Currently amended) The [[use]] method according to claim 13, wherein

R<sub>3</sub> is propoxy; and

R<sub>4</sub> and R<sub>5</sub> together with the phenyl ring to which they are attached, form a naphthalene-1-yl, indan-4-yl, isoquinolin-5-yl, isoquinolin-8-yl, 1,2,3,4-tetrahydroisoquinoli-8-yl, 2-alkoxycarbonyl-1,2,3,4-tetrahydroisoquinolin-8-yl or 5,6,7,8-tetrahydronaphthalen-1-yl moiety.

15. (Currently amended) The [[use]] method according to claim 9, [[or 10]] wherein

R<sub>3</sub>, R<sub>4</sub> and R<sub>5</sub> each are hydrogen; or

 $R_3$  and  $R_5$  each are hydrogen and  $R_4$  is methoxy; or  $R_3$  and  $R_4$  each are hydrogen and  $R_5$  is methoxy; or

R<sub>4</sub> and R<sub>5</sub> each are hydrogen and R<sub>3</sub> is *tert*-butyl, ethoxy, propoxy or butoxy; or

R<sub>3</sub> is hydrogen, R<sub>4</sub> is methoxy, and R<sub>5</sub> is hydroxy; or

 $R_4$  is hydrogen,  $R_3$  is methoxy or propoxy and  $R_5$  is methoxy or propoxy; or

R<sub>5</sub> is hydrogen, R<sub>3</sub> is methoxy, ethoxy, propoxy, butyloxy, *iso*-butyloxy, pentyloxy, hexyloxy, 3-methylbutoxy, 2-hydroxyethoxy, 2-methoxyethoxy, cyclopropylmethoxy or cyclobutylmethoxy and R<sub>4</sub> is methyl, methoxy, chloro or bromo.

16. (Currently amended) The [[use]] <u>method</u> according to claim 9, [[or 10]] wherein

R<sub>3</sub> is methoxy, propoxy, cyclopentyloxy, pent-1-ynyl or ethanesulfonyloxy; R<sub>4</sub> is methyl;

R<sub>5</sub> is hydroxy, methyl, pentyl, methoxy, propoxy, 2-methoxyethoxy, 2-hydroxyethoxy, 3-hydroxypropoxy, 4-hydroxybutoxy, 2,3-dihydroxypropoxy, 4-acetoxybutoxy, carboxymethoxy, 3-carboxypropoxy, 4-carboxybutoxy, 3-carboxy-2-hydroxypropoxy, 3-carboxy-2,3-dihydroxypropoxy, ethoxycarbonylmethoxy, 3-ethoxycarbonylpropoxy, 4-ethoxycarbonylbutoxy, 3-ethoxycarbonyl-2-hydroxypropoxy, 3-ethoxycarbonyl-2,3-dihydroxypropoxy, carbamoylmethoxy 3-*N*-ethylcarbamoylpropoxy, 4-*N*-ethylcarbamoylbutoxy, 2-*N*,*N*-dimethylaminoethoxy, 3-*N*,*N*-dmethylaminopropoxy, 2-(morpholin-4-yl)-ethyoxy, 2-(piperidin-1-yl)-ethoxy, 3-(morpholin-4-yl)-carbonylpropoxy, 4-(morpholin-4-yl)-carbonylbutoxy, 2,2-dimethyl[1,3]dioxolan-4-ylmethoxy or 2,2-dimethyl-4-carboxy[1,3]dioxolan-5-ylmethoxy; or

R<sub>4</sub> and R<sub>5</sub>, together with the phenyl ring to which they are attached, form a naphthalen-1-yl, 5,6,7,8-tetrahydronaphthalen-1-yl, indan-4-yl, 1,2,3,4,-tetraisoquinolin-8-yl or 2-*tert*-butoxycarbonyl-1,2,3,4,-tetraisoquinolin-8-yl moiety.

- 17. (Currently amended) The [[use]] <u>method</u> according to claim 1, [[or 3 of]] <u>wherein the compound is selected from the group consisting of:</u>
  - 4-(2,3-dimethyl-4-propoxy-benzylidene)-1-phenyl-pyrazolidine-3,5-dione;
  - 4-(4-methoxy-3-methyl-benzylidene)-1-phenyl-pyrazolidine-3,5-dione;
  - 4-(4-ethoxy-benzylidene)-1-phenyl-pyrazolidine-3,5-dione;
  - 4-(4-ethoxy-3-methoxy-benzylidene)-1-phenyl-pyrazolidine-3,5-dione;
  - 4-(2,4-dimethoxy-benzylidene)-1-phenyl-pyrazolidine-3,5-dione;
  - 4-naphthalen-2-ylmethylene-1-phenyl-pyrazolidine-3,5-dione;
  - 4-(4-tert-butyl-benzylidene)-1-phenyl-pyrazolidine-3,5-dione;
  - 4-(2,3-dimethyl-4-methoxybenzylidene)-1-phenyl-pyrazolidine-3,5-dione;
  - 4-(2,4-dimethoxy-3-methyl-benzylidene)-1-phenyl-pyrazolidine-3,5-dione;

```
4-(3-bromo-4-methoxy-benzylidene)-1-phenyl-pyrazolidine-3,5-dione;
             1-phenyl-4-(4-propoxy-benzylidene)-pyrazolidine-3,5-dione;
             4-(4-butoxy-benzylidene)-1-phenyl-pyrazolidine-3,5-dione;
             4-(4-ethoxy-3-methyl-benzylidene)-1-phenyl-pyrazolidine-3,5-dione;
             4-(3-methyl-4-propoxy-benzylidene)-1-phenyl-pyrazolidine-3,5-dione;
             4-(4-butoxy-3-methyl-benzylidene)-1-phenyl-pyrazolidine-3,5-dione;
             4-(4-hexyloxy-3-methyl-benzylidene)-1-phenyl-pyrazolidine-3,5-dione;
             4-(3-methyl-4-pentyloxy-benzylidene)-1-phenyl-pyrazolidine-3,5-dione;
             4-(4-cyclobutylmethoxy-3-methyl-benzylidene)-1-phenyl-pyrazolidine-3,5-
dione;
             4-[3-methyl-4-(3-methyl-butoxy)-benzylidene]-1-phenyl-pyrazolidine-3,5-
dione;
             4-(4-isobutoxy-3-methyl-benzylidene)-1-phenyl-pyrazolidine-3.5-dione:
             4-[4-(2-methoxy-ethoxy)-3-methyl-benzylidene]-1-phenyl-pyrazolidine-3,5-
dione;
             4-(3-chloro-4-propoxy-benzylidene)-1-phenyl-pyrazolidine-3,5-dione:
             4-[4-(2-hydroxy-ethoxy)-3-methyl-benzylidene]-1-phenyl-pyrazolidine-3,5-
dione;
             4-(4-cyclopropylmethoxy-3-methyl-benzylidene)-1-phenyl-pyrazolidine-3,5-
dione:
             4-(4-cyclopentyloxy-2,3-dimethyl-benzylidene)-1-phenyl-pyrazolidine-3,5-
dione;
             1-phenyl-4-(4-propoxy-5,6,7,8-tetrahydro-naphthalen-1-ylmethylene)-
pyrazolidine-3,5-dione;
             4-(2,3-dimethyl-4-pent-1-ynyl-benzylidene)-1-phenyl-pyrazolidine-3,5-
dione;
             4-(2,3-dimethyl-4-pentyl-benzylidene)-1-phenyl-pyrazolidine-3,5-dione;
             1-phenyl-4-(4-propoxy-naphthalen-1-ylmethylene)-pyrazolidine-3,5-dione;
```

1-phenyl-4-[1-(7-propoxy-indan-4-yl)-methylidene]-pyrazolidine-3,5-dione;

1-phenyl-4-[1-(5-propoxy-isoquinolin-8-yl)-methylidene]-pyrazolidine-3,5-

dione;

1-phenyl-4-[1-(8-propoxy-isoquinolin-5-yl)-methylidene]-pyrazolidine-3,5-dione;

4-[1-(2-*tert*-butoxycarbonyl-5-propoxy-1,2,3,4-tetrahydro-isoquinolin-8-yl)-methylidene]-1-phenyl-pyrazolidine-3,5-dione;

4-(2,3-dimethyl-4-ethanesulfonyloxy-benzylidene)-1-phenyl-pyrazolidine-3,5-dione;

4-[1-(2,4-dipropoxy-phenyl)-methylidene]-1-phenyl-pyrazolidine-3,5-dione;

4-[1-(2,6-dipropoxy-pyridin-3-yl)-methylidene]-1-phenyl-pyrazolidine-3,5-

dione;

4-[1-(2-hydroxy-3-methyl-4-propoxy-phenyl)-methylidene]-1-phenyl-pyrazolidine-3,5-dione;

4-[1-(2-methoxy-3-methyl-4-propoxy-phenyl)-methylidene]-1-phenyl-pyrazolidine-3,5-dione;

4-[1-(3-methyl-2,4-dipropoxy-phenyl)-methylidene]-1-phenyl-pyrazolidine-3,5-dione;

4-[1-[2-(2-methoxy-ethoxy)-3-methyl-4-propoxy-phenyl]-methylidene]-1-phenyl-pyrazolidine-3,5-dione;

4-[1-[2-(2-hydroxy-ethoxy)-3-methyl-4-propoxy-phenyl]-methylidene]-1-phenyl-pyrazolidine-3,5-dione;

4-[1-[2-(3-hydroxy-propoxy)-3-methyl-4-propoxy-phenyl]-methylidene]-1-phenyl-pyrazolidine-3,5-dione;

4-[1-[2-(4-acetoxy-butoxy)-3-methyl-4-propoxy-phenyl]-methylidene]-1-phenyl-pyrazolidine-3,5-dione;

4-[1-[2-(4-hydroxy-butoxy)-3-methyl-4-propoxy-phenyl]-methylidene]-1-phenyl-pyrazolidine-3,5-dione;

4-[1-[2-(ethoxycarbonyl-methoxy)-3-methyl-4-propoxy-phenyl]-methylidene]-1-phenyl-pyrazolidine-3,5-dione;

4-[1-[2-(carboxy-methoxy)-3-methyl-4-propoxy-phenyl]-methylidene]-1-phenyl-pyrazolidine-3,5-dione;

4-[1-[2-(2-amino-2-oxo-ethyloxy)-3-methyl-4-propoxy-phenyl]-methylidene]-1-phenyl-pyrazolidine-3,5-dione;

4-[1-[2-(3-ethoxycarbonyl-propoxy)-3-methyl-4-propoxy-phenyl]-methylidene]-1-phenyl-pyrazolidine-3,5-dione;

4-[1-[2-(3-carboxy-propoxy)-3-methyl-4-propoxy-phenyl]-methylidene]-1-phenyl-pyrazolidine-3,5-dione;

4-[1-[2-(4-ethylamino-4-oxo-butoxy)-3-methyl-4-propoxy-phenyl]-methylidene]-1-phenyl-pyrazolidine-3,5-dione;

4-[1-[3-methyl-2-(4-morpholin-4-yl-4-oxo-butoxy)-4-propoxy-phenyl]-methylidene]-1-phenyl-pyrazolidine-3,5-dione;

4-[1-[2-(4-ethoxycarbonyl-butoxy)-3-methyl-4-propoxy-phenyl]-methylidene]-1-phenyl-pyrazolidine-3,5-dione;

4-[1-[2-(4-carboxy-butyloxy)-3-methyl-4-propoxy-phenyl]-methylidene]-1-phenyl-pyrazolidine-3,5-dione;

4-[1-[2-(5-ethylamino-5-oxo-pentyloxy)-3-methyl-4-propoxy-phenyl]-methylidene]-1-phenyl-pyrazolidine-3,5-dione;

4-[1-[3-methyl-2-(5-morpholin-4-yl-5-oxo-pentyloxy)-4-propoxy-phenyl]-methylidene]-1-phenyl-pyrazolidine-3,5-dione;

4-[1-[2-(2-dimethylamino-ethoxy)-3-methyl-4-propoxy-phenyl]-methylidene]-1-phenyl-pyrazolidine-3,5-dione and its hydrochloride salt;

4-[1-[3-methyl-2-(2-morpholin-4-yl-ethoxy)-4-propoxy-phenyl]-methylidene]-1-phenyl-pyrazolidine-3,5-dione and its hydrochloride salt;

4-[1-[3-methyl-2-(2-piperidin-1-yl-ethoxy)-4-propoxy-phenyl]-methylidene]-1-phenyl-pyrazolidine-3,5-dione and its hydrochloride salt;

4-[1-[2-(3-dimethylamino-propoxy)-3-methyl-4-propoxy-phenyl]-methylidene]-1-phenyl-pyrazolidine-3,5-dione and its hydrochloride salt;

4-[1-[2-(2,2-dimethyl-[1,3]dioxolan-4-ylmethoxy)-3-methyl-4-propoxy-phenyl]-methylidene]-1-phenyl-pyrazolidine-3,5-dione;

4-[1-[2-((4R)-2,2-dimethyl-[1,3]dioxolan-4-ylmethoxy)-3-methyl-4-propoxy-phenyl]-methylidene]-1-phenyl-pyrazolidine-3,5-dione;

4-[1-[2-((4S)-2,2-dimethyl-[1,3]dioxolan-4-ylmethoxy)-3-methyl-4-propoxy-phenyl]-methylidene]-1-phenyl-pyrazolidine-3,5-dione;

4-[1-[2-((2*R*)-3-ethoxycarbonyl-2-hydroxy-propoxy)-3-methyl-4-propoxy-phenyl]-methylidene]-1-phenyl-pyrazolidine-3,5-dione;

4-[1-[2-((2*R*)-3-carboxy-2-hydroxy-propoxy)-3-methyl-4-propoxy-phenyl]-methylidene]-1-phenyl-pyrazolidine-3,5-dione;

4-[1-[2-((2S)-3-carboxy-2-hydroxy-propoxy)-3-methyl-4-propoxy-phenyl]-methylidene]-1-phenyl-pyrazolidine-3,5-dione;

4-[1-[2-((4*R*,5*S*)-4-carboxy-2,2-dimethyl-[1,3]dioxolan-5-ylmethoxy)-3-methyl-4-propoxy-phenyl]-methylidene]-1-phenyl-pyrazolidine-3,5-dione;

1-phenyl-4-[1-(5-propoxy-1,2,3,4-tetrahydro-isoquinolin-8-yl)-methylidene]-pyrazolidine-3,5-dione and its formiate salt;

4-[1-[2-(2,3-dihydroxy-propoxy)-3-methyl-4-propoxy-phenyl]-methylidene]-1-phenyl-pyrazolidine-3,5-dione;

4-[1-[2-((2S)-2,3-dihydroxy-propoxy)-3-methyl-4-propoxy-phenyl]-methylidene]-1-phenyl-pyrazolidine-3,5-dione;

4-[1-[2-((2*R*)-2,3-dihydroxy-propoxy)-3-methyl-4-propoxy-phenyl]-methylidene]-1-phenyl-pyrazolidine-3,5-dione;

4-[1-[2-((2S,3R)-2,3-dihydroxy-3-ethoxycarbonyl-propoxy)-3-methyl-4-propoxy-phenyl]-methylidene]-1-phenyl-pyrazolidine-3,5-dione;

4-[1-[2-((2S,3R)-3-carboxy-2,3-dihydroxy-propoxy)-3-methyl-4-propoxy-phenyl]-methylidene]-1-phenyl-pyrazolidine-3,5-dione;

ethyl 4-(4-benzylidene-3,5-dioxo-pyrazolidin-1-yl)-benzoate; ethyl 4-[4-(2-hydroxy-3-methoxy-benzylidene)-3,5-dioxo-pyrazolidin-1-yl]benzoate: ethyl 4-[4-(2-methoxy-benzylidene)-3,5-dioxo-pyrazolidin-1-yl]-benzoate; ethyl 4-[4-(3-methoxy-benzylidene)-3,5-dioxo-pyrazolidin-1-yl]-benzoate; ethyl 4-(3,5-dioxo-4-pyridin-3-ylmethylene-pyrazolidin-1-yl)-benzoate; ethyl 4-(3,5-dioxo-4-thiophen-3-ylmethylene-pyrazolidin-1-yl)-benzoate; ethyl 4-[4-(2,3-dimethyl-4-propoxy-benzylidene)-3,5-dioxo-pyrazolidin-1yl]-benzoate; 4-(3-methyl-4-propoxy-benzylidene)-1-pyridin-2-yl-pyrazolidine-3,5-dione; 4-(2,3-dimethyl-4-propoxy-benzylidene)-1-pyridin-2-yl-pyrazolidine-3,5dione; 1-(4-bromo-phenyl)-4-(2,3-dimethyl-4-propoxy-benzylidene)-pyrazolidine-3,5-dione; 4-(2,3-dimethyl-4-propoxy-benzylidene)-1-(4-methoxy-phenyl)pyrazolidine-3,5-dione; 4-[4-(2,3-dimethyl-4-propoxy-benzylidene)-3,5-dioxo-pyrazolidin-1-yl]benzonitrile; 4-(2,3-dimethyl-4-propoxy-benzylidene)-1-(4-fluoro-phenyl)-pyrazolidine-3,5-dione; 4-(2,3-dimethyl-4-propoxy-benzylidene)-1-(4-methyl-phenyl)-pyrazolidine-3,5-dione; 1-(2-chloro-phenyl)-4-(2,3-dimethyl-4-propoxy-benzylidene)-pyrazolidine-3,5-dione; 4-(2,3-dimethyl-4-propoxy-benzylidene)-1-(2-methyl-phenyl)-pyrazolidine-3,5-dione; 4-(2,3-dimethyl-4-propoxy-benzylidene)-pyrazolidine-3,5-dione; 4-(4-cyclopentyloxy-2,3-dimethyl-benzylidene)-pyrazolidine-3,5-dione;

4-(4-propoxy-5,6,7,8-tetrahydro-naphthalen-1-ylmethylene)-pyrazolidine-3,5-dione;

4-(2,3-dimethyl-4-pent-1-ynyl-benzylidene)-pyrazolidine-3,5-dione;

4-(2,3-dimethyl-4-pentyl-benzylidene)-pyrazolidine-3,5-dione;

4-(4-propoxy-naphthalen-1-ylmethylene)-pyrazolidine-3,5-dione;

4-(7-propoxy-indan-4-ylmethylene)-pyrazolidine-3,5-dione;

4-(2-methoxy-3-methyl-4-propoxy-benzylidene)-pyrazolidine-3,5-dione;

4-(3-methyl-2,4-dipropoxy-benzylidene)-pyrazolidine-3,5-dione;

4-(2,3-dimethyl-4-propoxy-benzylidene)-1-methyl-pyrazolidine-3,5-dione;

4-(2,3-dimethyl-4-propoxy-benzylidene)-1-pyridin-4-yl-pyrazolidine-3,5-

dione; and

1-acetyl-4-[1-(2,3-dimethyl-4-propoxy-phenyl)-methylidene]-pyrazolidine-3,5-dione.

18. (Currently Amended) Compounds A compound selected from the group consisting of: the general

a pyrazolidinedione derivative of formula (III'),

$$R_3$$
 $R_4$ 
 $R_5$ 

including their-geometric isomers thereof, [[and]] tautomers thereof, and mixtures thereof; as well as their-salts, esters and prodrugs mentioned in claim 1, or a salt, ester or prodrug of said compound,

wherein

R<sub>1</sub> is as defined in any one of claims 1, 2 and 4 to 6 <u>hydrogen</u>, optionally <u>substituted alkyl, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl or alkanoyl;</u>

R<sub>3</sub>' is alkyl, alkenyl, alkynyl, alkoxy, hydroxyalkoxy, alkoxyalkoxy, alkenyloxy, cycloalkylalkoxy or alkylsulfonyloxy;

R<sub>4</sub>' is halogen, hydroxy, alkyl or alkoxy; and

R<sub>5</sub>' is halogen, hydroxy, alkyl, alkoxy, alkoxyalkoxy, hydroxyalkoxy, dihydroxyalkoxy, alkanoyloxyalkoxy, carboxyalkoxy, carboxy-hydroxyalkoxy, carboxy-dihydroxyalkoxy, alkoxycarbonylalkoxy, alkoxycarbonyl-hydroxyalkoxy, alkoxycarbonyl-dihydroxyalkoxy, carbamoylalkoxy, *N*-alkylcarbamoylalkoxy, *N*,*N*-dialkyaminolalkoxy, morpholin-4-ylalkoxy, piperidin-1-ylalkoxy, morpholin-4-ylcarbonylalkoxy, 2,2-dialkyl[1,3]dioxolan-4-ylalkoxy or 2,2-dialkyl-4-carboxy[1,3]dioxolan-5-ylalkoxy; or

 $R_4$ ' and  $R_5$ ', together with the phenyl ring to which they are attached, form a fused, optionally substituted carbocyclic or heterocyclic ring system; with the proviso that if  $R_1$  is phenyl and  $R_3$ ' is methoxy,  $R_4$ ' and  $R_5$ ' may not both be methoxy.

 (Currently amended) compounds The compound according to claim 18, wherein

R<sub>1</sub> is other than alkanoyl;

R<sub>3</sub>' is alkyl, alkenyl, alkynyl, alkoxy, hydroxyalkoxy, alkoxyalkoxy, alkenyloxy, cycloalkoxy or cycloalkylalkoxy; and

R<sub>4</sub>' and R<sub>5</sub>', each independently of the other, are halogen, hydroxy, alkyl or alkoxy; or

R<sub>4</sub>' und R<sub>5</sub>', together with the phenyl ring to which they are attached, form a fused, optionally substituted carbocyclic or heterocyclic ring system.

20. (Currently amended) Compounds The compound according to claim 18, [[or 19]]

wherein

R<sub>3</sub>' is alkyl, alkenyl, alkynyl, alkoxy, cycloalkoxy, cycloalkylalkoxy, hydroxyalkoxy or alkoxyalkoxy,

R<sub>4</sub>' is halogen, alkyl or alkoxy, and

R<sub>5</sub>' is alkyl or alkoxy.

21. (Currently amended) Compounds The compound according to claim 20, wherein

R<sub>3</sub>' is methyl, ethyl, propyl, *iso*-propyl, butyl, *iso*-butyl, *tert*-butyl, pentyl, hexyl, but-1-enyl, pent-1-enyl, but-1-ynyl, pent-1-ynyl, methoxy, ethoxy, propoxy, butoxy, *iso*-butoxy, 3-methyl-butoxy, pentyloxy, cyclopentyloxy, hexyloxy, cyclopropylmethoxy, cyclobutylmethoxy, 2-hydroxy-ethoxy, 2-methoxy-ethoxy,

R<sub>4</sub>' is chloro, bromo, methyl or methoxy, and

 $R_5$ ' is methyl or methoxy.

22. (Currently amended) Compounds The compound according to claim 18, [[or 19]]

wherein

R<sub>3</sub>' is alkoxy, and

R<sub>4</sub>' and R<sub>5</sub>' together with the phenyl ring to which they are attached, form an optionally substituted naphthalene, tetrahydronaphthalene, indane, 1*H*-indene, isoquinoline, dihydro-benzo[1,4]dioxine or benzo[1,3]dioxole ring system.

23. (Currently amended) Compounds The compound according to claim 22, wherein R<sub>3</sub>' is propoxy, and

R<sub>4</sub>' and R<sub>5</sub>' together with the phenyl ring to which they are attached, form a naphthalene-1-yl, indan-4-yl, isoquinolin-5-yl, isoquinolin-8-yl, 1,2,3,4-tetrahydroisoquinoli-8-yl, 2-alkoxycarbonyl-1,2,3,4-tetrahydroisoquinoli-8-yl or 5,6,7,8-tetrahydronaphthalen-1-yl moiety.

24. (Currently amended) Compounds The compound according to claim 18, [[or 19]]

wherein

R<sub>3</sub>' is methoxy, propoxy, cyclopentyloxy, pent-1-ynyl or ethanesulfonyloxy; R<sub>4</sub>' is methyl;

R<sub>5</sub>' is hydroxy, methyl, pentyl, methoxy, propoxy, 2-methoxyethoxy, 2-hydroxyethoxy, 3-hydroxypropoxy, 4-hydroxybutoxy, 2,3-dihydroxypropoxy, 4-acetoxybutoxy, carboxymethoxy, 3-carboxypropoxy, 4-carboxybutoxy, 3-carboxy-2-hydroxypropoxy, 3-carboxy-2,3-dihydroxypropoxy, ethoxycarbonylmethoxy, 3-ethoxycarbonylpropoxy, 4-ethoxycarbonylbutoxy, 3-ethoxycarbonyl-2-hydroxypropoxy, 3-

ethoxycarbonyl-2,3-dihydroxypropoxy, carbamoylmethoxy 3-*N*-ethylcarbamoylpropoxy, 4-*N*-ethylcarbamoylbutoxy, 2-*N*,*N*-dimethylaminoethoxy, 3-*N*,*N*-dmethylaminopropoxy, 2-(morpholin-4-yl)-ethyoxy, 2-(piperidin-1-yl)-ethoxy, 3-(morpholin-4-yl)-carbonylpropoxy, 4-(morpholin-4-yl)-carbonylbutoxy, 2,2-dimethyl[1,3]dioxolan-4-ylmethoxy or 2,2-dimethyl-4-carboxy[1,3]dioxolan-5-ylmethoxy; or

R<sub>4</sub>' and R<sub>5</sub>', together with the phenyl ring to which they are attached, form a naphthalen-1-yl, 5,6,7,8-tetrahydronaphthalen-1-yl, indan-4-yl, 1,2,3,4,-tetraisoquinolin-8-yl or 2-*tert*-butoxycarbonyl-1,2,3,4,-tetraisoquinolin-8-yl moiety.

## 25. (Original) A compound selected from

- 4-[1-[2-((2S)-3-carboxy-2-hydroxy-propoxy)-3-methyl-4-propoxy-phenyl]-methylidene]-1-phenyl-pyrazolidine-3,5-dione;
- 4-[1-[2-((2R)-3-carboxy-2-hydroxy-propoxy)-3-methyl-4-propoxy-phenyl]-methylidene]-1-phenyl-pyrazolidine-3,5-dione;
- 4-[1-[2-(3-carboxy-propoxy)-3-methyl-4-propoxy-phenyl]-methylidene]-1-phenyl-pyrazolidine-3,5-dione;
- 4-[1-[2-(4-carboxy-butyloxy)-3-methyl-4-propoxy-phenyl]-methylidene]-1-phenyl-pyrazolidine-3,5-dione;
- 4-[1-[2-(2,3-dihydroxy-propoxy)-3-methyl-4-propoxy-phenyl]-methylidene]-1-phenyl-pyrazolidine-3,5-dione;
- 4-[1-[2-((2S)-2,3-dihydroxy-propoxy)-3-methyl-4-propoxy-phenyl]-methylidene]-1-phenyl-pyrazolidine-3,5-dione;
- 4-[1-[2-((2*R*)-2,3-dihydroxy-propoxy)-3-methyl-4-propoxy-phenyl]-methylidene]-1-phenyl-pyrazolidine-3,5-dione;
- 4-[1-[2-((2S,3R)-3-carboxy-2,3-dihydroxy-propoxy)-3-methyl-4-propoxy-phenyl]-methylidene]-1-phenyl-pyrazolidine-3,5-dione;

4-[1-[2-(5-ethylamino-5-oxo-pentyloxy)-3-methyl-4-propoxy-phenyl]-methylidene]-1-phenyl-pyrazolidine-3,5-dione;

- 4-[1-[2-(3-hydroxy-propoxy)-3-methyl-4-propoxy-phenyl]-methylidene]-1-phenyl-pyrazolidine-3,5-dione;
- 4-[1-[2-(4-hydroxy-butoxy)-3-methyl-4-propoxy-phenyl]-methylidene]-1-phenyl-pyrazolidine-3,5-dione;
- 4-[1-[2-(2-hydroxy-ethoxy)-3-methyl-4-propoxy-phenyl]-methylidene]-1-phenyl-pyrazolidine-3,5-dione;
- 4-[1-[2-((2S,3R)-2,3-dihydroxy-3-ethoxycarbonyl-propoxy)-3-methyl-4-propoxy-phenyl]-methylidene]-1-phenyl-pyrazolidine-3,5-dione;
- 4-[1-[2-(ethoxycarbonyl-methoxy)-3-methyl-4-propoxy-phenyl]-methylidene]-1-phenyl-pyrazolidine-3,5-dione; and
- 4-[1-[3-methyl-2-(4-morpholin-4-yl-4-oxo-butoxy)-4-propoxy-phenyl]-methylidene]-1-phenyl-pyrazolidine-3,5-dione.
- 26. (Original) A compound selected from 1-phenyl-4-[1-(5-propoxy-isoquinolin-8-yl)-methylidene]-pyrazolidine-3,5-dione;
- 4-[1-[2-(4-ethylamino-4-oxo-butoxy)-3-methyl-4-propoxy-phenyl]-methylidene]-1-phenyl-pyrazolidine-3,5-dione;
- 4-[1-[2-(4-ethoxycarbonyl-butoxy)-3-methyl-4-propoxy-phenyl]-methylidene]-1-phenyl-pyrazolidine-3,5-dione;
- 4-[1-[2-((2R)-3-ethoxycarbonyl-2-hydroxy-propoxy)-3-methyl-4-propoxy-phenyl]-methylidene]-1-phenyl-pyrazolidine-3,5-dione;
- 4-[1-[2-(4-acetoxy-butoxy)-3-methyl-4-propoxy-phenyl]-methylidene]-1-phenyl-pyrazolidine-3,5-dione;
- 4-[1-[2-(3-ethoxycarbonyl-propoxy)-3-methyl-4-propoxy-phenyl]-methylidene]-1-phenyl-pyrazolidine-3,5-dione;

4-[1-[2-(2-methoxy-ethoxy)-3-methyl-4-propoxy-phenyl]-methylidene]-1-phenyl-pyrazolidine-3,5-dione;

4-[1-[3-methyl-2-(5-morpholin-4-yl-5-oxo-pentyloxy)-4-propoxy-phenyl]-methylidene]-1-phenyl-pyrazolidine-3,5-dione;

1-phenyl-4-[1-(8-propoxy-isoquinolin-5-yl)-methylidene]-pyrazolidine-3,5-dione;

4-[1-[2-(2-amino-2-oxo-ethyloxy)-3-methyl-4-propoxy-phenyl]-methylidene]-1-phenyl-pyrazolidine-3,5-dione;

4-[1-[3-methyl-2-(2-morpholin-4-yl-ethoxy)-4-propoxy-phenyl]-methylidene]-1-phenyl-pyrazolidine-3,5-dione and its hydrochloride salt;

4-[1-[2-(2,2-dimethyl-[1,3]dioxolan-4-ylmethoxy)-3-methyl-4-propoxy-phenyl]-methylidene]-1-phenyl-pyrazolidine-3,5-dione;

4-(2,3-dimethyl-4-propoxy-benzylidene)-1-phenyl-pyrazolidine-3,5-dione;

4-[1-[2-((4*R*,5*S*)-4-carboxy-2,2-dimethyl-[1,3]dioxolan-5-ylmethoxy)-3-methyl-4-propoxy-phenyl]-methylidene]-1-phenyl-pyrazolidine-3,5-dione;

4-[1-[2-((4*R*)-2,2-dimethyl-[1,3]dioxolan-4-ylmethoxy)-3-methyl-4-propoxy-phenyl]-methylidene]-1-phenyl-pyrazolidine-3,5-dione;

4-[1-[2-(3-dimethylamino-propoxy)-3-methyl-4-propoxy-phenyl]-methylidene]-1-phenyl-pyrazolidine-3,5-dione and its hydrochloride salt;

1-phenyl-4-[1-(7-propoxy-indan-4-yl)-methylidene]-pyrazolidine-3,5-dione;

1-phenyl-4-(4-propoxy-5,6,7,8-tetrahydro-naphthalen-1-ylmethylene)-pyrazolidine-3,5-dione;

1-phenyl-4-[1-(5-propoxy-1,2,3,4-tetrahydro-isoquinolin-8-yl)-methylidene]-pyrazolidine-3,5-dione and its formiate salt;

4-[1-[2-(2-dimethylamino-ethoxy)-3-methyl-4-propoxy-phenyl]-methylidene]-1-phenyl-pyrazolidine-3,5-dione and its hydrochloride salt;

4-[1-[2-(carboxy-methoxy)-3-methyl-4-propoxy-phenyl]-methylidene]-1-phenyl-pyrazolidine-3,5-dione;

4-[1-[2-((4S)-2,2-dimethyl-[1,3]dioxolan-4-ylmethoxy)-3-methyl-4-propoxy-phenyl]-methylidene]-1-phenyl-pyrazolidine-3,5-dione;

4-(3-methyl-2,4-dipropoxy-benzylidene)-pyrazolidine-3,5-dione;

4-[1-(3-methyl-2,4-dipropoxy-phenyl)-methylidene]-1-phenyl-pyrazolidine-3,5-dione;

4-(4-propoxy-5,6,7,8-tetrahydro-naphthalen-1-ylmethylene)-pyrazolidine-3,5-dione;

4-[1-(2-methoxy-3-methyl-4-propoxy-phenyl)-methylidene]-1-phenyl-pyrazolidine-3,5-dione;

4-(2-methoxy-3-methyl-4-propoxy-benzylidene)-pyrazolidine-3,5-dione;

4-(7-propoxy-indan-4-ylmethylene)-pyrazolidine-3,5-dione;

4-[1-(2-*tert*-butoxycarbonyl-5-propoxy-1,2,3,4-tetrahydro-isoquinolin-8-yl)-methylidene]-1-phenyl-pyrazolidine-3,5-dione; and

4-(2,3-dimethyl-4-propoxy-benzylidene)-1-(4-fluoro-phenyl)-pyrazolidine-3,5-dione.

27. (Original) A compound selected from

1-phenyl-4-(4-propoxy-naphthalen-1-ylmethylene)-pyrazolidine-3,5-dione;

4-[1-[3-methyl-2-(2-piperidin-1-yl-ethoxy)-4-propoxy-phenyl]-methylidene]-1-phenyl-pyrazolidine-3,5-dione and its hydrochloride salt;

4-(2,4-dimethoxy-3-methyl-benzylidene)-1-phenyl-pyrazolidine-3,5-dione;

4-(2,3-dimethyl-4-ethanesulfonyloxy-benzylidene)-1-phenyl-pyrazolidine-3,5-dione;

4-(2,3-dimethyl-4-propoxy-benzylidene)-1-pyridin-2-yl-pyrazolidine-3,5-dione;

4-(2,3-dimethyl-4-propoxy-benzylidene)-pyrazolidine-3,5-dione;

4-(2,3-dimethyl-4-methoxybenzylidene)-1-phenyl-pyrazolidine-3,5-dione;

4-(2,3-dimethyl-4-pent-1-ynyl-benzylidene)-1-phenyl-pyrazolidine-3,5-

dione;

```
4-(4-propoxy-naphthalen-1-ylmethylene)-pyrazolidine-3,5-dione;
```

4-[4-(2,3-dimethyl-4-propoxy-benzylidene)-3,5-dioxo-pyrazolidin-1-yl]-benzonitrile:

4-[1-(2-hydroxy-3-methyl-4-propoxy-phenyl)-methylidene]-1-phenyl-pyrazolidine-3,5-dione;

4-(2,3-dimethyl-4-pentyl-benzylidene)-1-phenyl-pyrazolidine-3,5-dione;

4-(2,3-dimethyl-4-pentyl-benzylidene)-pyrazolidine-3,5-dione;

1-(2-chloro-phenyl)-4-(2,3-dimethyl-4-propoxy-benzylidene)-pyrazolidine-

3,5-dione;

4-(2,3-dimethyl-4-pent-1-ynyl-benzylidene)-pyrazolidine-3,5-dione;

4-(2,3-dimethyl-4-propoxy-benzylidene)-1-pyridin-4-yl-pyrazolidine-3,5-

dione;

4-(2,3-dimethyl-4-propoxy-benzylidene)-1-(4-methyl-phenyl)-pyrazolidine-

3,5-dione;

4-(4-cyclopentyloxy-2,3-dimethyl-benzylidene)-pyrazolidine-3,5-dione;

4-(4-cyclopentyloxy-2,3-dimethyl-benzylidene)-1-phenyl-pyrazolidine-3,5-

dione;

4-(2,3-dimethyl-4-propoxy-benzylidene)-1-(4-methoxy-phenyl)-pyrazolidine-3,5-dione;

1-(4-bromo-phenyl)-4-(2,3-dimethyl-4-propoxy-benzylidene)-pyrazolidine-3,5-dione;

4-(2,3-dimethyl-4-propoxy-benzylidene)-1-(2-methyl-phenyl)-pyrazolidine-3,5-dione;

4-(2,3-dimethyl-4-propoxy-benzylidene)-1-methyl-pyrazolidine-3,5-dione; ethyl 4-[4-(2,3-dimethyl-4-propoxy-benzylidene)-3,5-dioxo-pyrazolidin-1-yll-benzoate; and

1-acetyl-4-[1-(2,3-dimethyl-4-propoxy-phenyl)-methylidene]-pyrazolidine-3,5-dione.

- 28. (Cancelled).
- 29. (Currently amended) A pharmaceutical composition containing a comprising the compound according to any one of claims 18 to 27 claim 18 and a pharmaceutically inert carrier.
- 30. (Currently amended) The use according to claim 1 or 3 of compounds A method for preventing or treating a disease or a condition associated with platelet aggregation, said method comprising administering to a mammal in need thereof the compound according to any one of claims 18 to 23 claim 18.
- 31. (Currently amended) A process for the manufacture of compounds the compound according to any one of claims 18 to 27 which comprises claim 18, comprising condensing a pyrazolidinedione of the general formula (IV), as shown in the following reaction scheme wherein R<sub>1</sub>, R<sub>3'</sub>, R<sub>4'</sub> and R<sub>5'</sub> are as defined in claim 18,

with an aldehyde of the above general formula (V), any reactive group which may be present in the compounds of formulae IV and V being appropriately protected, and, if necessary, splitting off from the condensation product any protecting group(s) which may be undesired.

32. (Currently amended) [[A]] <u>The process of claim 31, wherein the</u> pyrazolidinedione of the general formula (IV) <u>as indicated in claim 31, is</u> selected from the group <u>consisting of</u>:

1-pyridin-2-yl-pyrazolidine-3,5-dione;

```
4-(3,5-dioxo-pyrazolidin-1-yl)-benzonitrile; and 1-pyridin-4-yl-pyrazolidine-3,5-dione.
```

- 33. (Currently amended) [[An]] <u>The process of claim 31, wherein the</u> aldehyde of the general formula (V) as indicated in claim 31 is selected from the group consisting of:
  - 4-cyclopentyloxy-2,3-dimethyl-benzaldehyde;
  - 4-propoxy-5,6,7,8-tetrahydro-naphthalene-1-carbaldehyde;
  - 2,3-dimethyl-4-pent-1-ynyl-benzaldehyde;
  - 2,3-dimethyl-4-pentyl-benzaldehyde;
  - 7-propoxy-indan-4-carbaldehyde;
  - 5-propoxy-isoquinoline-8-carbaldehyde;
  - 8-propoxy-isoquinoline-5-carbaldehyde;
  - 2-tert-butyloxycarbonyl-8-formyl-5-propoxy-1,2,3,4-tetrahydroisoquinoline;
  - 2,3-dimethyl-4-ethanesulfonyloxybenzaldehyde;
  - 2-hydroxy-3-methyl-4-propoxy-benzaldehyde;
  - 2-methoxy-3-methyl-4-propoxy-benzaldehyde;
  - 2-(2-methoxy-ethoxy)-3-methyl-4-propoxy-benzaldehyde;
  - 2-(2-hydroxy-ethoxy)-3-methyl-4-propoxy-benzaldehyde;
  - 2-(3-hydroxy-propoxy)-3-methyl-4-propoxy-benzaldehyde;
  - 2-(4-acetoxy-butoxy)-3-methyl-4-propoxy-benzaldehyde;
  - 2-(4-hydroxy-butoxy)-3-methyl-4-propoxy-benzaldehyde;
  - ethyl (6-formyl-2-methyl-3-propoxy-phenoxy)-acetate;
  - (6-formyl-2-methyl-3-propoxy-phenoxy)-acetic acid;
  - 2-(6-formyl-2-methyl-3-propoxy-phenoxy)-acetamide;
  - ethyl 4-(6-formyl-2-methyl-3-propoxy-phenoxy)-butanoate;
  - 4-(6-formyl-2-methyl-3-propoxy-phenoxy)-butanoic acid;
  - 4-(6-formyl-2-methyl-3-propoxy-phenoxy)-butanoic acid ethylamide;
  - 3-methyl-2-(4-morpholin-4-yl-4-oxo-butoxy)-4-propoxy-benzaldehyde;

ethyl 5-(6-formyl-2-methyl-3-propoxy-phenoxy)-pentanoate;

5-(6-formyl-2-methyl-3-propoxy-phenoxy)-pentanoic acid;

5-(6-formyl-2-methyl-3-propoxy-phenoxy)-pentanoic acid ethylamide;

3-methyl-2-(5-morpholin-4-yl-5-oxo-pentyloxy)-4-propoxy-benzaldehyde;

2-(2-dimethylamino-ethoxy)-3-methyl-4-propoxy-benzaldehyde and its hydrochloride salt;

3-methyl-2-(2-morpholin-4-yl-ethoxy)-4-propoxy-benzaldehyde and its hydrochloride salt;

3-methyl-2-(2-piperidin-1-yl-ethoxy)-4-propoxy-benzaldehyde and its hydrochloride salt;

2-(3-dimethylamino-propoxy)-3-methyl-4-propoxy-benzaldehyde and its hydrochloride salt;

2-(2,2-dimethyl-[1,3]dioxolan-4-ylmethoxy)-3-methyl-4-propoxy-benzaldehyde;

2-((4R)-2,2-dimethyl-[1,3]dioxolan-4-ylmethoxy)-3-methyl-4-propoxy-benzaldehyde;

2-((4S)-2,2-dimethyl-[1,3]dioxolan-4-ylmethoxy)-3-methyl-4-propoxy-benzaldehyde;

ethyl (3R)-4-(6-formyl-2-methyl-3-propoxy-phenoxy)-3-hydroxy-butanoate; (3R)-4-(6-formyl-2-methyl-3-propoxy-phenoxy)-3-hydroxy-butanoic acid; ethyl (3S)-4-(6-formyl-2-methyl-3-propoxy-phenoxy)-3-hydroxy-butanoate; (3S)-4-(6-formyl-2-methyl-3-propoxy-phenoxy)-3-hydroxy-butanoic acid; methyl (4R,5S)-5-(6-formyl-2-methyl-3-propoxy-phenoxymethyl)-2,2-dimethyl-[1,3]dioxolane-4-carboxylate;

(4*R*,5*S*)-5-(6-formyl-2-methyl-3-propoxy-phenoxymethyl)-2,2-dimethyl-[1,3]dioxolane-4-carboxylic acid.